Navigation Links
buy in Biological Technology

Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target

KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of CombiMatrix Corporation (Nasdaq: CBMX ) with a BUY rating and an $18.00 price target. CombiMatrix is a life sciences company focused on developing and commercializing in vitro genetic diagnostic...

Roche Proposes to buy Full Stake in Genentech - Interview With Chairman

LONDON, July 21 /PRNewswire-FirstCall/ -- Roche, the healthcare company, announced today that it has proposed to acquire the outstanding publicly held interest in biotech company Genentech for US$89.00 per share in cash, or a total payment of approximately US$43.7bn to equity holders of Genent...

Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price

BOCA RATON, Fla., Aug. 29 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, initiated research coverage on CryoCor, Inc. (Nasdaq: CRYO ) with a Strong Buy rating and a 12-18 month price target of $6.00. John M. Putnam, ...

Merge eFilm to buy Ohio firm in $14M Deal

The acquisition will allow Merge eFilm to offer an integrated PAC (picture achieving and communications) and RIS (radiology information system) solution to its target market of hospitals and imaging centers. "The acquisition of RIS Logic is an important strategic milestone in our evolution as a...

GE Cleared Buy Instrumentarium

WAUKESHA, WI.--GE Medical Systems has received required regulatory approvals for the $2.3 billion acquisition of Instrumentarium Corporation. The company has agreed to divest of two divisions of the company they are acquiring. GE Medical Systems, a medical imaging equipment manufacturer plans to...

Metavante and First Data to buy PIN-debit company NYCE

MILWAUKEE Metavante Corporation and First Data Corporation jointly announced Monday they have signed a definitive agreement that provides for the purchase of substantially all of the stock of NYCE Corporation by Metavante for approximately $610 million in cash. As the majority shareholder of...

Third Wave to buy back stock

MADISON Third Wave Technologies announced Tuesday that it will repurchase up to 5% of its outstanding stock. The board of directors approved purchases on the open market or in private transactions in a show of confidence in the company's potential. "Third Wave's stock repurchase program unders...

Renaissance to buy computer companion maker AlphaSmart for $57m

Educational software maker Renaissance Learning, Inc. , has agreed to acquire California-based AlphaSmart, Inc. , a provider of portable learning devices for K-12 students, for $57 million. Renaissance, based in Wisconsin Rapids, Wisconsin, plans to maintain the AlphaSmart name and operate the...

Invitrogen to buy Norwegian biotech with operations in Brown Deer

Invitrogen : 4,000 employees worldwide. Headquartered in Carlsbad, California. Dynal : 400+ employees worldwide, 87 in North America, 65 in Brown Deer. Headquartered in Oslo, Norway. Brown Deer, Wis. California-based Invitrogen Corp. plans to acquire Dynal Biotech ASA , whose U.S. operati...

Massachusetts firm to buy UW spinoff Bone Care for $600 million

Madison, Wis. Massachusetts-based Genzyme Corp. said on Wednesday it has agreed to buy Bone Care International , a University of Wisconsin-Madison biotech spinoff, for $600 million in cash. Bone Care and Genzyme, a 24-year-old company with annual revenues of more than $2 billion and almost...

Metavante to buy California software developer

Milwaukee, Wis. - Metavante Corp ., the banking and payments technology subsidiary of Marshall and Ilsley Corp ., is in the final stages of acquiring VICOR, Inc. , a Richmond, Calif.-based provider of corporate payment processing software. VICOR is being pursued, in part, to enable Metavant...

How Best Buy said bye to burnout, hello to results

For years I had been focusing on the wrong currency. I was always looking to see if people were here. I should have been looking at what they were getting done." - John J. T. Thompson, senior vice president, Best Buy. It's about time. A large corporation with a strong workaholic and face-ti...

Before deciding how to pay for K-12 schools, let's determine what to buy

Madison, Wis. - It's not surprising that Gov. Jim Doyle and the Republican-led Legislature are still at odds over how the state's latest budget will treat public school districts across Wisconsin. Doyle thinks he saved K-12 districts from cuts without hurting taxpayers; the Republicans believe ...

Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes

...siting EDGAR on the SEC website at www.sec.gov . This communication shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlaw...

ADVENTRX Pharmaceuticals Announces Financing

... the exclusive placement agent for the transaction. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to regist...

Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock

...ting as sole book-running manager for the offering. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Idenix, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be...

Human Genome Sciences Announces Closing of Public Offering

...ued pursuant to an effective shelf registration statement. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Human Genome Sciences, Inc., nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicita...

CuraGen Reports Second Quarter 2009 Financial Results

...omes available. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to reg...

TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction

...ses above. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to reg...

Human Genome Sciences Announces Pricing of Public Offering of Common Stock

...ued pursuant to an effective shelf registration statement. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Human Genome Sciences, Inc., nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicita...

Human Genome Sciences Announces Proposed Public Offering of Common Stock

...ing as joint book-running managers for the offering. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Human Genome Sciences, Inc., nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicita...

OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering

...thell, WA 98021-7617, Attention: Chief Financial Officer. This news release shall not constitute an offer to sell or the solicitation of an offer to buy the common stock of OncoGenex, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale ...

Cell Therapeutics, Inc. Announces Exercise of Overallotment

...loor, New York, New York 10020, or by calling (212) 356-0549. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or s...

Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement

...ot yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective....se shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdictio...

Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

...loor, New York, New York 10020, or by calling (212) 356-0549. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or s...

Response Genetics Announces $4 Million Private Placement

...he shares of common stock issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy Response Genetics, Inc.'s common stock. About Response Genetics, Inc. Response Genetics, Inc. ("RGI") (the "Company") (Nasdaq: R...

Miami Beach Real Estate Attorney Opens Miami Real Estate Brokerage for International Luxury Miami Beach Condo Buyers From Distressed Sellers

...ont condos and homes. "Cash buyers rule the current market" notes Folland, adding "luxury buyers feel now is the best time to buy ultra premium properties in Miami Beach". Folland also points out that international buyers have always been interested in Miami Beach, Florida,...

Nile Therapeutics, Inc. Completes $3.4 Million Private Placement

...cluding the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registrat...

Pharmacyclics Announces Subscription Price for Rights Offering

...rn Daylight Time, unless extended by the Company. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or ...

Progenitor Cell Therapy Appoints VP of Manufacturing Operations

...ease visit www.progenitorcelltherapy.com . Disclaimer This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to suc...

Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement

...cluding the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registrat...

Verenium Completes Amendment to 8% Senior Convertible Notes

...8-K, filed on July 1, 2009 with the Securities and Exchange Commission. This press release is not an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. ...

Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait

...ou and Shanghai," said Han Chih-yang, Excalibur's deputy. "We are full of confidence for the future of cross-strait tourism, so we are seeking to buy two larger ships for launching regular cross-strait service," he said. Jack Qin, the President and CEO of EFT BioTech Holdings, stated, "We are e...

OncoGenex Pharmaceuticals Files Shelf Registration Statement

... been filed with the British Columbia Securities Commission but they have not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the shelf registration statement becomes effective and a final receipt has been issued for the MJDS prospectus. This p...

AEterna Zentaris Receives US$10 Million from Institutional Investors

...c., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of AEterna Zentaris' common shares or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation ...

Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program

... HC International is a focused and dedicated organization that acts as a premier information resource for institutional investors, hedge funds, buy and sell-side analysts, small to large brokerage firms and accredited investors. HC International helps to position their clients' corporate informati...

ADVENTRX Pharmaceuticals Announces Closing of Financing

...as the exclusive placement agent for the transaction. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to regist...

China Biologic Products Closes the $9.6 Million Private Placement

... Securities and Exchange Commission on June 5, 2009. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. ...

ADVENTRX Pharmaceuticals Announces Financing

...as the exclusive placement agent for the transaction. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to regist...

China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million

...es and Exchange Commission on or about June 5, 2009. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. ...
Other Tags
(Date:4/17/2014)... Marc Andr Gauthier and Professor Luca Razzari of ... been awarded large grants from the John R. ... Innovation (CFI) for the acquisition of state-of-the-art biotech ... added matching grants from the Ministre de l,Enseignement ... de la Technologie (MESRST). These new laboratories will ...
(Date:4/17/2014)... hydrogen sulfide in order to properly multiply and form ... Center for Craniofacial Molecular Biology at the Herman Ostrow ... principal investigator on the project, said the presence of ... of calcium ions. The essential ions activate a chain ... creation of new bone tissue, and keeps the breakdown ...
(Date:4/17/2014)... the Amazon help create tinderbox conditions for wildfires ... forest loss during drought years, according to a ... in the Amazon could reach a "tipping point" ... to large-scale loss of trees, making recovery more ... Penn State. , "We documented one of the ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
(Date:4/17/2014)... new study has found that India,s shocking rates of ... farmers who are clinging to tiny smallholdings less ... crops, such as cotton and coffee, that are highly ... a range of previous case studies that point to ... following the ,liberalisation, of the nation,s economy during the ...
(Date:4/17/2014)... Giving patients adrenaline after they suffer a cardiac arrest ... of surviving long-term, according to new research conducted at ... who have a cardiac arrest get adrenaline, which has ... decades," said Dr. Steve Lin, an emergency physician and ... in medical treatment, long-term survival rates of patients who ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... of the embryo. It begins as a glob of identical ... become the cells of our lungs, muscles, nerves and all ... a feat of reverse tissue engineering, Stanford University researchers have ... cells to proliferate and transform into all of the specialized ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... in solid tumors, including long-term patient follow-up, have been ... Issue 232). The data demonstrate robust antibody and T ... with very advanced cancers and suggest that CDX-1401 may ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
Other Contents